Covid-19: GSK and Sanofi join forces


The two pharmaceutical giants Sanofi and GSK have joined forces by combining their innovative technology to develop a vaccine against Covid-19.

This collaboration is one of many other initiatives currently underway to combat the pandemic.

According to Paul Hudson, Chief Executive of Sanofi, "As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone." By combining their technologies, the two groups ultimately hope to develop sufficient quantities of a vaccine to combat Covid-19.

GSK will be involved in research, using its adjuvants technology developed on the Rixensart site in Belgium. As this technique allows production on a greater scale, the Belgian site will play a key role in this collaboration. For its part, Sanofi will provide its Covid-19 S-protein antigen, obtained thanks to technology that has made it possible to obtain an exact genetic replica of the proteins on the surface of the virus.

They hope to launch clinical tests in the second half of 2020 and, if these are successful, make the vaccine available in 2021. They also undertake to ensure that the vaccine is available at an affordable price and on an international scale.

In conclusion, to use the motto of Belgium, it seems that unity is strength!